AAAI

Advanced Accelerator Applications (AAA), a Novartis company, is a global leader in the field of radioligand therapy (RLT) and molecular imaging. The company develops, produces, and commercializes targeted radiopharmaceuticals for the treatment and diagnosis of oncology diseases, particularly neuroendocrine tumors and prostate cancer. Its flagship products include Lutathera for GEP-NETs and Pluvicto for metastatic castration-resistant prostate cancer. AAA operates an extensive network of manufacturing sites across Europe and North America, specializing in the production of lutetium-177 and fluorine-18 based therapies and diagnostics. The company is a pioneer in the 'theranostics' approach, which integrates diagnostic imaging with targeted therapy to improve patient outcomes.